查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1544103

全球临床前影像市场（In-VIVO）

Preclinical Imaging (In-VIVO)
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球临床前影像 (In-VIVO) 市场预计将达到 14 亿美元

全球临床前影像 (In-VIVO) 市场预计 2023 年将达到 10 亿美元，预计到 2030 年将达到 14 亿美元，在 2023-2030 年分析期间复合年增长率为 4.8%。临床前影像模式是本报告分析的细分市场之一，预计复合年增长率为 5.2%，到分析期结束时将达到 9.01 亿美元。分析期间，临床前成像试剂领域的复合年增长率预计为 4.2%。

美国市场预估为2.787亿美元，中国预期复合年增长率为4.6%

预计 2023 年美国临床前影像 (In-VIVO) 市场规模将达到 2.787 亿美元。中国作为全球第二大经济体，预计2030年市场规模将达2.252亿美元，2023年至2030年复合年增长率为4.6%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 4.6% 和 3.8%。在欧洲，德国的复合年增长率预计为 4.1%。

全球临床前影像（体内）市场 - 主要趋势与驱动因素总结

临床前影像（In-VIVO）：生物医学研究的进展

临床前成像（In-VIVO）是指使用先进​​的成像技术来视觉化和研究活体动物模型中的生物过程，主要用于生物医学研究目的。这种诊断影像在人体临床试验之前进行，有助于研究人员了解疾病机制、评估新药的有效性并即时监测治疗效果。临床前研究中常用的影像方法包括磁振造影（MRI）、正子断层扫描（PET）、电脑断层扫描（CT）以及生物发光和萤光成像等光学成像技术。临床前影像的重要性在于提供对健康和疾病背后的生物过程的详细了解，使研究人员能够在药物开发和生物医学研究的其他领域做出明智的决定。临床前影像可以对疾病进展和治疗效果进行非侵入性监测，在医学进步中发挥重要作用。

科技进步如何改善临床前影像（体内）？

技术进步显着提高了临床前成像能力，提高了显像模式的解析度和能力。高场 MRI 磁体和高灵敏度 PET检测器等成像硬体的创新提高了影像的空间和时间分辨率，使生物过程能够更详细地可视化。结合两种或多种成像技术（例如 PET/CT 和 MRI/PET）的多模态影像系统的发展，使研究人员能够同时获得互补的资料，从而更全面地了解疾病机制和治疗效果。分子造影剂（包括靶向显影剂和放射性示踪剂）的进步提高了成像的特异性，并使特定分子途径和细胞过程的可视化成为可能。此外，透过将人工智慧（AI）和机器学习演算法整合到影像分析中，提高了处理和解释复杂影像资料的能力，从而产生更准确和高效的研究结果。这些技术进步扩大了临床前影像的范围和影响，使其成为生物医学研究的重要工具。

临床前影像（In-VIVO）的主要用途和优点是什么？

临床前影像 (In-VIVO) 用于各种研究领域，并提供许多好处，可促进疾病了解和新治疗方法的开发。在肿瘤学研究中，临床前影像可以对肿瘤生长和转移进行非侵入性跟踪，帮助研究人员即时评估癌症治疗的有效性。在神经科学领域，MRI 和 PET 等影像技术用于研究大脑结构和功能，从而深入了解阿兹海默症和帕金森氏症等神经系统疾病。心血管研究受益于临床前成像，透过可视化心臟和血管功能，这有助于心臟病研究和新心血管药物的开发。此外，临床前影像也用于药物动力学和动态研究，以监测药物在体内的分布和作用。临床前影像的主要优点包括能够非侵入性地即时监测生物过程、透过纵向研究减少动物的使用以及产生对临床研究有用的高解析度资料。这些优势使临床前成像成为现代生物医学研究的重要组成部分。

推动临床前影像（体内）市场成长的因素有哪些？

临床前成像（In-VIVO）市场的成长受到多种因素的推动。由于临床前影像为临床研究和药物开发提供了重要讯息，因此对更准确和非侵入性方法来研究疾病机制和评估药物疗效的需求不断增长。此外，提高成像模式的分辨率、灵敏度和功能的技术进步也在推动市场成长。製药和生物技术产业的扩张，特别是个人化医疗领域的扩张，导致对临床前影像工具的需求增加。此外，人们越来越关注减少研究中动物的使用，再加上临床前成像能够对同一动物进行长期研究，这进一步推动了市场渗透。包括人工智慧和机器学习在内的先进资料分析技术的整合正在提高临床前成像的效用并推动其持续成长。这些因素加上成像技术的不断创新，正在推动临床前影像（In-VIVO）市场的持续成长。

受访企业范例（共38家）

  • Aspect Imaging Ltd.
  • Bruker Corp.
  • Idex Health & Science LLC
  • Mauna Kea Technologies
  • Mediso Ltd.
  • Milabs BV
  • Miltenyi Biotech GmbH
  • MR Solutions
  • New England Biolabs
  • PerkinElmer, Inc.
  • Siemens AG
  • Trifoil Imaging, Inc.
  • FujiFilm VisualSonics, Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他领域

第四章 比赛

简介目录
Product Code: MCP14177

Global Preclinical Imaging (In-VIVO) Market to Reach US$1.4 Billion by 2030

The global market for Preclinical Imaging (In-VIVO) estimated at US$1.0 Billion in the year 2023, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2023-2030. Preclinical Imaging Modalities, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$900.1 Million by the end of the analysis period. Growth in the Preclinical Imaging Reagents segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$278.7 Million While China is Forecast to Grow at 4.6% CAGR

The Preclinical Imaging (In-VIVO) market in the U.S. is estimated at US$278.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$225.2 Million by the year 2030 trailing a CAGR of 4.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Preclinical Imaging (In-VIVO) Market - Key Trends and Drivers Summarized

Preclinical Imaging (In-VIVO): Advancing Biomedical Research

Preclinical imaging (in-vivo) refers to the use of advanced imaging techniques to visualize and study biological processes in live animal models, primarily for biomedical research purposes. This imaging is conducted before clinical trials in humans, helping researchers understand disease mechanisms, evaluate the efficacy of new drugs, and monitor treatment effects in real-time. Common imaging modalities used in preclinical research include magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and optical imaging techniques such as bioluminescence and fluorescence imaging. The importance of preclinical imaging lies in its ability to provide detailed insights into the biological processes underlying health and disease, enabling researchers to make informed decisions in drug development and other areas of biomedical research. By allowing non-invasive monitoring of disease progression and treatment response, preclinical imaging plays a crucial role in the advancement of medical science.

How Are Technological Advancements Enhancing Preclinical Imaging (In-VIVO)?

Technological advancements have significantly improved the capabilities of preclinical imaging, enhancing both the resolution and functionality of imaging modalities. Innovations in imaging hardware, such as higher-field MRI magnets and more sensitive PET detectors, have increased the spatial and temporal resolution of images, allowing for more detailed visualization of biological processes. The development of multimodal imaging systems, which combine two or more imaging techniques (e.g., PET/CT or MRI/PET), has enabled researchers to simultaneously capture complementary data, providing a more comprehensive understanding of disease mechanisms and treatment effects. Advances in molecular imaging agents, including targeted contrast agents and radiotracers, have improved the specificity of imaging, allowing for the visualization of specific molecular pathways and cellular processes. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms into image analysis has enhanced the ability to process and interpret complex imaging data, facilitating more accurate and efficient research outcomes. These technological improvements have expanded the applications and impact of preclinical imaging, making it an indispensable tool in biomedical research.

What Are the Key Applications and Benefits of Preclinical Imaging (In-VIVO)?

Preclinical imaging (in-vivo) is used in various research areas, offering numerous benefits that advance the understanding of disease and the development of new treatments. In oncology research, preclinical imaging allows for the non-invasive tracking of tumor growth and metastasis, helping researchers evaluate the effectiveness of cancer therapies in real-time. In neuroscience, imaging techniques such as MRI and PET are used to study brain structure and function, providing insights into neurological disorders such as Alzheimer's disease and Parkinson's disease. Cardiovascular research benefits from preclinical imaging through the visualization of heart and blood vessel function, aiding in the study of heart disease and the development of new cardiovascular drugs. Additionally, preclinical imaging is used in pharmacokinetics and pharmacodynamics studies to monitor the distribution and action of drugs within the body. The primary benefits of preclinical imaging include the ability to conduct non-invasive, real-time monitoring of biological processes, the reduction of animal use through longitudinal studies, and the generation of high-resolution data that can inform clinical research. These advantages make preclinical imaging a critical component of modern biomedical research.

What Factors Are Driving the Growth in the Preclinical Imaging (In-VIVO) Market?

The growth in the preclinical imaging (in-vivo) market is driven by several factors. The increasing demand for more precise and non-invasive methods to study disease mechanisms and evaluate drug efficacy is a significant driver, as preclinical imaging provides critical insights that inform clinical research and drug development. Technological advancements that enhance the resolution, sensitivity, and functionality of imaging modalities are also propelling market growth. The expansion of the pharmaceutical and biotechnology industries, particularly in the area of personalized medicine, is contributing to the increased demand for preclinical imaging tools. Additionally, the growing emphasis on reducing animal use in research, coupled with the ability of preclinical imaging to enable longitudinal studies in the same animals, is further boosting market adoption. The integration of advanced data analysis techniques, including AI and machine learning, is enhancing the utility of preclinical imaging, driving its continued growth. These factors, combined with the ongoing innovation in imaging technologies, are driving the sustained growth of the preclinical imaging (in-vivo) market.

Select Competitors (Total 38 Featured) -

  • Aspect Imaging Ltd.
  • Bruker Corp.
  • Idex Health & Science LLC
  • Mauna Kea Technologies
  • Mediso Ltd.
  • Milabs B.V.
  • Miltenyi Biotech GmbH
  • MR Solutions
  • New England Biolabs
  • PerkinElmer, Inc.
  • Siemens A.G.
  • Trifoil Imaging, Inc.
  • FujiFilm VisualSonics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Preclinical Imaging (In-VIVO) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Technological Advancements in Imaging Modalities Propel Market Growth
    • Rising Prevalence of Chronic Diseases Expands Addressable Market Opportunity
    • Growing Adoption of Multimodal Imaging Solutions Throws the Spotlight on Innovation
    • Focus on Drug Discovery and Development Accelerates Market Dynamics
    • Expansion of Contract Research Organizations (CROs) Boosts Market Prospects
    • Increasing Use of Imaging in Oncology Research Propels Market Expansion
    • Adoption of AI and Machine Learning in Image Analysis Drives Market Dynamics
    • Focus on Non-invasive Imaging Techniques Sustains Market Growth
    • Growing Investments in Preclinical Studies for Rare Diseases Expands Market Reach
    • Focus on Improving Image Resolution and Accuracy Enhances Market Opportunities
    • Regulatory Support for Preclinical Research Activities Propels Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Preclinical Imaging (In-VIVO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Preclinical Imaging (In-VIVO) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Preclinical imaging modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Preclinical imaging modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Preclinical imaging modalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Preclinical imaging reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Preclinical imaging reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Preclinical imaging reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Preclinical Imaging (In-VIVO) Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • JAPAN
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • CHINA
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: China 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • EUROPE
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Preclinical Imaging (In-VIVO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Preclinical Imaging (In-VIVO) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • FRANCE
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: France 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • GERMANY
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Rest of Europe Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Rest of Europe 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Asia-Pacific 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of World Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of World 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030

IV. COMPETITION